Eli Lilly and Company (LLY) announced promising topline results from the QWINT-1 and QWINT-3 Phase 3 studies, which assessed the efficacy of the once-weekly basal insulin, efsitora alfa, in adults with type 2 diabetes. Both studies achieved their primary objectives.The QWINT-1 study investigated the efficacy and safety of efsitora compared to the once-daily insulin glargine over a period of 52 weeks. Insulin-naive adults with type 2 diabetes were randomly assigned to receive either efsitora once weekly or insulin glargine once daily. The study successfully reached its primary endpoint, demonstrating that efsitora achieved a non-inferior reduction in A1C levels compared to insulin glargine at week 52.In the QWINT-3 study, the efficacy and safety of once-weekly efsitora were compared to once-daily insulin degludec over 78 weeks in adults who were already receiving basal insulin for type 2 diabetes. Participants were randomized to receive either efsitora once weekly or insulin degludec once daily. Similar to QWINT-1, this study also met its primary endpoint, showing that efsitora provided non-inferior A1C reduction compared to insulin degludec at week 26.Additionally, both QWINT-1 and QWINT-3 studies demonstrated that the overall safety and tolerability of efsitora were comparable to those of daily basal insulin therapies for the treatment of type 2 diabetes.The material has been provided by InstaForex Company – www.instaforex.com
- Canadian Market Notably Lower; Energy Stocks Fall - September 10, 2024
- Nasdaq, S&P 500 Remain Little Changed, Dow More Firmly Negative - September 10, 2024
- Boeing To Launch First-Of-Its-Kind Quantum Entanglement Swapping Satellite In 2026 - September 10, 2024
